China Today: Biogenerics in China: An Evolving Industry - China's large domestic market potential and its competence in producing biogenerics are driving its future direction - BioPharm International

ADVERTISEMENT

China Today: Biogenerics in China: An Evolving Industry
China's large domestic market potential and its competence in producing biogenerics are driving its future direction


BioPharm International
Volume 20, Issue 6

To assure continued industry growth, Chinese authorities recognize the importance of enhancing their country's IP protection systems for both domestic and foreign biologics. The fact that Chinese companies are using the court systems and lawsuits to seek remedies indicates a major change in the Chinese pharmaceuticals business environment. China's large domestic market potential and its solid competence in producing biogenerics are key factors driving its future direction.

REFERENCES:

1. The journey of generic drugs to overturn innovative drugs (in Chinese). Medicine Economic News. 2004; Dec. 30.

2. http:// http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html.

3. http:// http://www.sfda.gov.cn/cmsweb/webportal/W4291/A64003794.html.

4. China's bio-tech and industry appears rapid expansion trend. A report (in Chinese). 2006; Apr. 22. Available at http:// http://www.chinabgao.com/freereports/10264.html.

5. Rader R. Biopharmaceutical products in US and European markets. 5th Ed. BioPlan Associates, Inc. 2006.

Eric Langer is president of BioPlan Associates, Rockville, MD, 301.921.9074.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lilly to Acquire Novartis Animal Health
April 22, 2014
Novartis and GSK Trade Assets
April 22, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here